Stocks
Amicus Therapeutics Financial Statements (FOLD) |
||||||||||
| Amicus Therapeuticssmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 02.03.2020 | 01.03.2021 | 24.02.2022 | 01.03.2023 | 28.02.2024 | 06.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 182.2 | 260.9 | 305.5 | 329.2 | 399.4 | 493.7 | |||
| Operating Income, bln rub | -300.7 | -243.9 | -199.9 | -204.4 | -73.5 | 11.3 | ||||
| EBITDA, bln rub | ? | -332.3 | -243.0 | -202.9 | -199.6 | -92.1 | -9.20 | |||
| Net profit, bln rub | ? | -356.4 | -276.9 | -250.5 | -236.6 | -151.6 | -104.7 | |||
| OCF, bln rub | ? | -250.4 | -233.3 | -202.5 | -166.6 | -69.1 | 3.46 | |||
| CAPEX, bln rub | ? | 20.0 | 3.23 | 3.88 | 3.77 | 7.44 | 7.55 | |||
| FCF, bln rub | ? | -270.4 | -236.5 | -206.4 | -170.3 | -76.5 | 1.73 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 461.0 | 473.7 | 471.0 | 495.1 | 427.7 | 421.2 | ||||
| Cost of production, bln rub | 22.0 | 31.0 | 34.5 | 38.6 | 37.3 | 55.9 | ||||
| R&D, bln rub | 286.4 | 308.4 | 272.0 | 276.7 | 152.4 | 114.2 | ||||
| Interest expenses, bln rub | 18.9 | 22.4 | 32.5 | 37.1 | 50.1 | 50.5 | ||||
| Assets, bln rub | 850.2 | 886.5 | 905.1 | 724.2 | 777.9 | 786.6 | ||||
| Net Assets, bln rub | ? | 476.4 | 286.4 | 307.4 | 123.0 | 160.2 | 178.8 | |||
| Debt, bln rub | 210.2 | 441.7 | 440.1 | 452.1 | 445.1 | 444.7 | ||||
| Cash, bln rub | 452.7 | 483.3 | 482.5 | 293.6 | 286.2 | 249.8 | ||||
| Net debt, bln rub | -242.5 | -41.5 | -42.4 | 158.5 | 158.9 | 194.9 | ||||
| Ordinary share price, rub | 9.74 | 23.1 | 11.6 | 12.2 | 14.2 | 10.9 | ||||
| Number of ordinary shares, mln | 240.4 | 258.9 | 271.4 | 289.1 | 295.2 | 304.7 | ||||
| Market cap, bln rub | 2 342 | 5 977 | 3 135 | 3 529 | 4 188 | 3 333 | ||||
| EV, bln rub | ? | 2 099 | 5 936 | 3 093 | 3 688 | 4 347 | 3 528 | |||
| Book value, bln rub | 256 | 66 | 87 | -98 | -58 | -37 | ||||
| EPS, rub | ? | -1.48 | -1.07 | -0.92 | -0.82 | -0.51 | -0.34 | |||
| FCF/share, rub | -1.12 | -0.91 | -0.76 | -0.59 | -0.26 | 0.01 | ||||
| BV/share, rub | 1.06 | 0.25 | 0.32 | -0.34 | -0.20 | -0.12 | ||||
| EBITDA margin, % | ? | -182.3% | -93.1% | -66.4% | -60.6% | -23.1% | -1.86% | |||
| Net margin, % | ? | -195.6% | -106.1% | -82.0% | -71.9% | -38.0% | -21.2% | |||
| FCF yield, % | ? | -11.5% | -3.96% | -6.58% | -4.83% | -1.83% | 0.05% | |||
| ROE, % | ? | -74.8% | -96.7% | -81.5% | -192.3% | -94.6% | -58.5% | |||
| ROA, % | ? | -41.9% | -31.2% | -27.7% | -32.7% | -19.5% | -13.3% | |||
| P/E | ? | -6.57 | -21.6 | -12.5 | -14.9 | -27.6 | -31.8 | |||
| P/FCF | -8.66 | -25.3 | -15.2 | -20.7 | -54.7 | 1 930 | ||||
| P/S | ? | 12.8 | 22.9 | 10.3 | 10.7 | 10.5 | 6.75 | |||
| P/BV | ? | 9.16 | 91.1 | 36.2 | -36.1 | -72.1 | -90.1 | |||
| EV/EBITDA | ? | -6.32 | -24.4 | -15.2 | -18.5 | -47.2 | -383.7 | |||
| Debt/EBITDA | 0.73 | 0.17 | 0.21 | -0.79 | -1.73 | -21.2 | ||||
| R&D/CAPEX, % | 1 431% | 9 558% | 7 004% | 7 347% | 2 048% | 1 513% | ||||
| CAPEX/Revenue, % | 11.0% | 1.24% | 1.27% | 1.14% | 1.86% | 1.53% | ||||
| Amicus Therapeutics shareholders | ||||||||||
